We have been reporting periodically on the YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral litigation, as we have been doing since 2009 when the first lawsuits against Bayer were filed.
The most recent Bayer information about the YAZ / Yasmin drug injury litigation was published by Bayer on July 29, 2015 in the Bayer Interim Report for the Second Quarter of 2015. From that document we get this update:
Yasmin™/YAZ™: As of July 17, 2015, the number of claimants in the pending lawsuits and claims in the United States totaled about 4,000 (excluding claims already settled). Claimants allege that they have suffered personal injuries, some of them fatal, from the use of Bayer’s drospirenone-containing oral contraceptive products such as Yasmin™ and/or YAZ™ or from the use of Ocella™ and/or Gianvi™, generic versions of Yasmin™ and YAZ™, respectively, marketed by Barr Laboratories, Inc. in the United States.
As of July 17, 2015, Bayer had reached agreements, without admission of liability, to settle approximately 9,900 claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) for a total amount of about US$1.97 billion. Bayer will continue to consider the option of settling such claims after a case-specific analysis of medical records. At present, about 590 such claims are under review…. As of July 17, 2015, about 1,200 of the 4,000 above-mentioned claimants alleged arterial thromboembolic injuries.
We expect to find updated settlement numbers in the Bayer Interim Report for the Third Quarter of 2015, which is currently scheduled to be published on October 29, 2015.[Read this article in full at original source]
Strictly Confidential, No Obligation.